Drugs / Na-ASP-2
Na-ASP-2
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00473967 | May 2007 → Mar 2008 | hookworm infectious disease | Albert B. Sabin Vaccine Institute | Terminated | No outcome recorded |
| Phase 1 | NCT00120081 | Apr 2005 → Sep 2006 | hookworm infectious disease | Baylor College of Medicine | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00603889 | Mar → May 2008 | allergic disease, hookworm infectious disease | Albert B. Sabin Vaccine Institute | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Na-ASP-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00473967 ↗ |
| Known as | Na-ASP-2 hookworm vaccine | “Randomized, placebo-controlled, double-blind trial of the Na-ASP-2 hookworm vaccine in unexposed adults.” PMID 18396361 ↗ Mar 2008 |
| Known as | Na-ASP-2/Alhydrogel Hookworm Vaccine | “Biological: Na-ASP-2/Alhydrogel Hookworm Vaccine” NCT00120081 ↗ |
| Known as | Necator americanus Ancylostoma Secreted Protein-2 | “Necator americanus Ancylostoma Secreted Protein-2 (Na-ASP-2) is a leading larval-stage hookworm vaccine candidate.” PMID 18396361 ↗ Mar 2008 |
| Modality | Vaccine | “Na-ASP-2 hookworm vaccine” NCT00120081 ↗ |
| Route | Intramuscular | “randomized to receive intramuscular injections of either Na-ASP-2 or saline placebo” PMID 18396361 ↗ Mar 2008 |